Mikofenolatna Kiselina Accord

Mycophenolic Acid, the active ingredient in Mikofenolatna Kiselina Accord, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by suppressing immune cell activity.

GNH USA supplies Mikofenolatna Kiselina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory compliance support.

Mycophenolic Acid is used to manage immune‑mediated conditions, particularly in transplant and autoimmune disease contexts. - Organ transplant rejection: reduces the risk of acute rejection in kidney, heart and liver transplants. - Lupus nephritis: helps control renal inflammation in systemic lupus erythematosus. - Graft‑versus‑host disease prophylaxis: used to prevent GVHD in bone marrow transplantation.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may affect hydration. - Headache: transient cranial discomfort. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Leukopenia: reduced white blood cell count. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Severe infection: opportunistic infections requiring immediate medical attention. - Malignancy: potential increased risk of certain cancers with long‑term use. - Bone marrow suppression: pancytopenia or aplastic anemia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare viral brain infection. - Severe hypersensitivity: rash, angioedema or anaphylaxis.

Patients should be monitored regularly for safety and efficacy. - Blood counts: perform routine complete blood count monitoring. - Renal function: assess serum creatinine and glomerular filtration rate. - Live vaccines: avoid administration while on therapy. - Pregnancy: discuss potential risks with a healthcare professional before use. - Hepatic impairment: consider dose adjustment in patients with liver disease. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Potential drug interactions may affect efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: may reduce absorption of the drug. - Azathioprine: combined immunosuppression can increase risk of bone marrow suppression. - Live vaccines: may lead to severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Rifampin: may decrease plasma concentrations of Mycophenolic Acid. - Valganciclovir: may increase risk of cytopenias. - Cyclosporine or tacrolimus: may require dose adjustments and close therapeutic drug monitoring.